Skip to main content
HR 909 114th Congress House Health Administrative law and regulatory procedures Administrative remedies Advisory bodies Congressional oversight Consumer affairs Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Executive agency funding and structure Food and Drug Administration (FDA) Government information and archives Government studies and investigations Health care coverage and access

Andrea Sloan CURE Act

Introduced: February 12, 2015 Introduced by: McCaul, Michael T. Republican · Texas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 13, 2015
Referred to the Subcommittee on Health.
Feb 12, 2015
Referred to the House Committee on Energy and Commerce.
Feb 12, 2015
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act

Amends the Federal Food, Drug, and Cosmetic Act to require the sponsor of an “investigational drug” (which is a drug that is designated as a breakthrough therapy, fast track product, infectious disease product, or drug for a rare disease or condition) to submit to the Food and Drug Administration (FDA) and make available to the public the sponsor's policy on requests for expanded access to the unapproved drug, including the minimum criteria for considering or approving requests and the time needed to make a decision.

Requires an investigational drug sponsor to explain a denied request for expanded access to the person who made the request.

Directs the Department of Health and Human Services to establish an Expanded Access Task Force. Requires the Task Force and the Government Accountability Office (GAO) to evaluate patient access to investigational drugs and make recommendations for improving access.

Directs the FDA to finalize the draft guidance entitled “Expanded Access to Investigational Drugs for Treatment Use--Qs & As,” taking into account reports from the Task Force and GAO.
What's happening now February 13, 2015

Referred to the Subcommittee on Health.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 4
All 4 Democratic 2 Republican 2
R
Cramer, Kevin
North Dakota · Feb 1, 2016
 D
Peters, Scott H.
California · May 5, 2015
 R
Griffith, H. Morgan
Virginia · Feb 12, 2015
 D
Matsui, Doris O.
California · Feb 12, 2015
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 909: Andrea Sloan CURE Act. 114th Congress. Open America. https://openamerica.io/bill/114-HR-909/
MLA
"H.R. 909: Andrea Sloan CURE Act." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-909/.
Bluebook (legal)
H.R. 909, 114th Cong. (2026), https://openamerica.io/bill/114-HR-909/.
Markdown link
[H.R. 909: Andrea Sloan CURE Act](https://openamerica.io/bill/114-HR-909/)
Report a problem